Latest Financial Results News

Australian Clinical Labs reported a modest revenue dip but achieved growth in earnings and margins in 1H26, while updating FY26 guidance and addressing wage increases mandated by the Fair Work Commission.

Ansell Limited reported a robust 61.5% surge in net profit for the first half of FY26, driven by operational efficiencies and strategic acquisitions, while announcing a planned CEO transition.

BlueScope Steel reported a robust first half of FY2026 with underlying EBIT soaring 81% to $557.5 million and announced a $3.00 per share shareholder return plan, while decisively rejecting a $30 per share takeover proposal.

Contact Energy has announced a $525 million equity raise to accelerate its renewable energy projects, following a strong first half of FY26 with significant profit growth and strategic acquisitions.

ECP Emerging Growth Limited reported a 6.9% portfolio loss for H1 2025, underperforming the ASX Small Ordinaries Index, yet declared a fully franked interim dividend and teased a significant special dividend.

Touch Ventures Limited reported a $4.6 million net loss for 2025, driven by investment impairments and foreign exchange impacts, while appointing Gannet Capital as its new investment manager to revamp its portfolio strategy.

WCM Global Growth Limited reported a net operating profit of $22.9 million for H1 FY2026 and announced an increased fully franked interim dividend, reinforcing its progressive dividend policy.

WCM Global Growth Limited reported a 51% drop in net profit for H1 FY2026 but announced an increased fully franked interim dividend, reflecting confidence in its investment strategy. The company’s portfolio outperformed its benchmark over 12 months despite a softer half-year return.

Katana Capital Limited has reported a remarkable 672% increase in half-year profit after tax to $5.8 million, driven by strong investment income and gains. The company maintains its quarterly dividend at 0.5 cents per share, reflecting confidence in its ongoing strategy.

AVITA Medical reported a mixed fourth quarter with revenue pressures easing and full-year growth, underpinned by a new $60 million credit facility and advancing clinical trials.

AVITA Medical closed 2025 with steady revenue growth and over 80% gross margin, setting the stage for a confident revenue forecast of up to US$85 million in 2026. The company also secured a new debt facility with improved terms, underpinning its growth ambitions.

AVITA Medical reported steady Q4 losses amid reimbursement challenges but achieved 11% revenue growth for 2025 and secured a $60 million credit facility to fuel future expansion.